SGLT2 Inhibitors and Finerenone: How Kidney Protection Got Better in 2026

For thirty years, ACE inhibitors and ARBs were essentially the only drugs that protected kidneys. In 2026, SGLT2 inhibitors and finerenone have transformed chronic kidney disease (CKD) care — and most CKD patients are still not on the right combination.

The new pillars of CKD care

• SGLT2 inhibitors (dapagliflozin, empagliflozin) — kidney-protective in CKD with or without diabetes; reduce progression to dialysis by ~30%.
• Finerenone — non-steroidal mineralocorticoid receptor antagonist proven to slow CKD progression in T2D with albuminuria.
• ACEi/ARB remains foundational — but is no longer enough on its own.

Who should be on what

• T2D + CKD: ACEi/ARB + SGLT2 + finerenone is the modern triple-therapy backbone.
• Non-diabetic CKD with proteinuria: ACEi/ARB + SGLT2 has strong evidence (DAPA-CKD, EMPA-KIDNEY).
• Heart failure overlap: SGLT2 helps both — one drug, two diseases.

Practical points patients should know

• A small initial creatinine bump with SGLT2 or ACEi/ARB is expected and not a reason to stop.
• Volume status matters — be cautious in dehydration; sick-day rules apply (hold during severe vomiting/diarrhoea).
• Genital infection counselling — uncommon but easily managed; do not let it stop SGLT2 use unless severe.

What this means for patients and practising clinicians

If you have CKD — especially with diabetes or significant proteinuria — and you are not on an SGLT2 inhibitor, ask your nephrologist or physician about it. In 2026, *not* offering this conversation is the medical lapse, not the other way around.

*This article was drafted by the DocSite AI Team and reviewed for clinical accuracy. It is general medical information, not personal medical advice. For decisions about your own care, please consult a qualified specialist on DocSite.*